EX-10.11 15 a2238822zex-10_11.htm EX-10.11 HIGHLY CONFIDENTIAL EXECUTION VERSION [***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as...Co-Development and Collaboration Agreement • May 5th, 2020
This Amendment No. 5 (this “Amendment No. 5”) to the Current Agreement (as defined below) is made as of January 22, 2018 (the “Amendment Effective Date”)
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 1”) is made and entered into as of the day of , 2008 (the “Amendment Effective Date”), between
AMENDMENT NO. 3 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 3”) is made and entered into as of the 1st day of July, 2010 (the “Amendment Effective Date”), between
AMENDMENT NO. 2 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 2”) is made and entered into as of the 18th day of December, 2008 (the “Amendment Effective Date”), between
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. CO- DEVELOPMENT AND...Co-Development and Collaboration Agreement • October 9th, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
This CO-DEVELOPMENT AND COLLABORATION AGREEMENT (this “Agreement”), dated as of April 9, 2014 (the “Effective Date”), is entered into by and between AVEO PHARMACEUTICALS, INC. (“AVEO”), a Delaware corporation having a principal office at 650 E. Kendall Street, Cambridge, Massachusetts 02142, and Biodesix, Inc. (“Biodesix”), a Delaware corporation having a principal office located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301. AVEO and Biodesix are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 4 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)Co-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 4”) is made and entered into as of the 20th day of December, 2010 (the “Amendment Effective Date”), between
ContractCo-Development and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
Institutional Conflict of Interest Management and Monitoring Plan: RaySearch Laboratories ABCo-Development and Collaboration Agreement • November 19th, 2018
The University of Texas MD Anderson (MD Anderson) and RaySearch Laboratories AB (RaySearch) are parties to a Co-Development and Collaboration Agreement (Agreement) pursuant to which MD Anderson has agreed to conduct four research projects using various RaySearch Software at MD Anderson (Studies).
FIRST AMENDMENT TO CO-DEVELOPMENT AND COLLABORATION AGREEMENTCo-Development and Collaboration Agreement • November 4th, 2016 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment (“First Amendment”) is made effective as of October 14, 2016 (“Amendment Effective Date”) and shall serve to modify that certain Co-Development and Collaboration Agreement dated April 9, 2014 (“Agreement”) by and between AVEO Pharmaceuticals, Inc. (“AVEO”) and Biodesix, Inc. (“Biodesix”). AVEO and Biodesix are sometimes referred to individually as a “Party” and collectively as the “Parties”.
